BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 12447674)

  • 1. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
    Selim AG; El-Ayat G; Wells CA
    Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
    Elayat G; Selim AG; Wells CA
    Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
    Selim AG; El-Ayat G; Naase M; Wells CA
    Breast; 2002 Dec; 11(6):466-72. PubMed ID: 14965711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different proliferative patterns characterize different preinvasive breast lesions.
    Viacava P; Naccarato AG; Bevilacqua G
    J Pathol; 1999 Jul; 188(3):245-51. PubMed ID: 10419590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. bcl-2 expression in the spectrum of preinvasive breast lesions.
    Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
    Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
    Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
    J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between EBV infection and expression of cellular proteins c-Myc, Bcl-2, and Bax in gastric carcinomas.
    Lima MA; Ferreira MV; Barros MA; Pardini MI; Ferrasi AC; Mota RM; Rabenhorst SH
    Diagn Mol Pathol; 2008 Jun; 17(2):82-9. PubMed ID: 18382371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
    Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
    Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z
    Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
    Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
    BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases.
    Moriya T; Sakamoto K; Sasano H; Kawanaka M; Sonoo H; Manabe T; Ito J
    Mod Pathol; 2000 Jan; 13(1):13-8. PubMed ID: 10658905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
    Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
    In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferative activity (Ki-67), WT p53, Bcl-2 expression and their relationship to the tumor grade, in invasive ductal breast carcinomas.
    Kalogeraki A; Garbagnati F; Santinami M; Zoras O
    In Vivo; 2002; 16(2):141-4. PubMed ID: 12073773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apocrine adenosis: a precursor of aggressive breast cancer?
    Wells CA; McGregor IL; Makunura CN; Yeomans P; Davies JD
    J Clin Pathol; 1995 Aug; 48(8):737-42. PubMed ID: 7560201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenes, granules and breast cancer: what has c-myc to do with apocrine changes?
    Schmitt FC; Reis-Filho JS
    Breast; 2002 Dec; 11(6):463-5. PubMed ID: 14965710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.